Kevin Dondarski from Deloitte Consulting discusses how changes in industry trends are causing pharma companies to explore new market opportunities provided by the rise of GLP-1 medications.
Kevin Dondarski
Advertisement
Kevin Dondarski is a partner at Deloitte Consulting, life sciences strategy practice.
Articles by Kevin Dondarski
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Industry’s Communication and Engagement with FDA
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
4
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
5